Apr 8 2010
BeaconEquity.com announces an investment report featuring biopharmaceutical company Genta Inc. (OTCBB:GETA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/GETA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/BeaconEquity
Genta Inc. (GETA) is a biopharmaceutical company engaged in research and development of novel drugs for the treatment of various cancers. The Company intends to commercialize its pharmaceutical technologies worldwide. The Company's drugs include Ganite® (gallium nitrate injection), Genasense® (oblimersen sodium) injection, Tesetaxel and oral gallium.
In the report, the analyst notes:
"Since its inception, the Company has incurred annual operating losses due to research and development, testing, production, logistics, regulatory and marketing costs relating to the Company's drug-candidate pipeline of drugs. Through December 31, 2009, the Company has accrued deficits of $1.03 billion, with further annual deficits expected until one or more of the Company's drug candidates achieves significant commercialization success.
"On April 6, the Company announced that it has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA) for the Company's Tesetaxel candidate drug compound developed for the treatment of patients afflicted with advanced gastric cancer."
SOURCE Beacon Equity Research
BMI's influence on disease pathogenesis uncovered in new research